Trial reportESMO open2026
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.
Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04357873 (Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data are available on the role of human papillomavirus circulating tumor DNA (HPV-ctDNA) as a pharmacodynamic marker to monitor the response to treatment in the recurrent/metastatic (R/M) setting. Our study aimed to investigate the sensitivity and pharmacodynamic value of HPV-ctDNA levels during treatment in patients with R/M HPV-related squamous cell carcinoma (SCC) treated with pembrolizumab in combination with vorinostat (PEVO trial, NCT04357873). MATERIALS AND
methodsPlasma samples were prospectively collected from 57 patients with HPV-related SCC before treatment initiation and every 6 weeks until disease progression. HPV-ctDNA was quantified by droplet digital PCR. The levels before treatment were analyzed according to the patient and tumor characteristics. Landmark analyses were carried out to study the association between dynamic changes in HPV-ctDNA and progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
resultsHPV-ctDNA was detected before treatment in all patients (n = 57) with HPV-related SCC. HPV-ctDNA levels correlated with the number of HPV copies in tumor tissue (P < 0.001). Higher levels of HPV-ctDNA in plasma samples were observed in anal cancer than in other tumor types (P < 0.001), and in patients with distant metastases with or without locoregional recurrence than in patients with locoregional recurrence alone (P = 0.02). The increase in HPV-ctDNA levels during treatment was associated with a lower ORR (P = 0.01) and shorter PFS and OS (both P = 0.01).
conclusionThese findings reveal that dynamic HPV-ctDNA variation levels during treatment have a pharmacodynamic value and may help monitor treatment response in patients with advanced HPV-related SCC from different locations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.